Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

Most of 23andMe bought for a lot more than one could have thought–and why? Yesterday, the board of 23andMe confirmed that they have a court-approved definitive agreement for the sale of their core ...

Regeneron Pharmaceuticals announced it won the bankruptcy auction for key assets of 23andMe, according to Benzinga. The $256 ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

To acquire Personal Genome Service, Total Health and Research Services business lines, and its Biobank and associated assets.

Regeneron Pharmaceuticals REGN has emerged as the successful bidder in the bankruptcy auction for most of the assets of 23andMe Holding Co., a prominent player in human genetics and biotechnology.

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

At MIT, one genome researcher is testing a different approach. Bin Zhang, associate professor of chemistry and the leader of MIT's Zhang Lab, is using artificial intelligence to "unfold" complex ...

Government scientists appear to have found an alternative to contentious genetically modified (GM) crops with the launch of two genome-edited varieties of rice—a key staple and export.